Related Experiment Video
Updated: Jul 9, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Vaccine therapy for prostate cancer
Guru Sonpavde1, David M Spencer, Kevin M Slawin
1U.S. Oncology Research and the Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX 77598, USA. guru.sonpavde@usoncology.com
Abstract:
Immunotherapy with vaccines represents a novel, targeted nontoxic modality for the therapy of prostate cancer. Systemic immune responses to candidate prostate cancer antigens have been induced in a tumor that has been conventionally viewed as refractory to immunotherapy. Autologous dendritic cell vaccines expressing prostate-specific antigens have shown promising clinical outcomes in a randomized trial in metastatic androgen independent prostate cancer. Other vaccine approaches include granulocyte-macrophage colony-stimulating factor modified tumor cell vaccines and poxvirus vaccines. A combination of vaccines with chemotherapy, radiotherapy, and other biologic agents is also being evaluated. Efforts to optimize vaccine approaches and select ideal patient populations need to continue because there is no evidence supporting a single superior approach.
Insights
Prostate cancer immunotherapy using vaccines shows promise, inducing immune responses against cancer antigens. Dendritic cell vaccines demonstrate positive outcomes in metastatic prostate cancer patients.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Prostate cancer has traditionally been considered resistant to immunotherapy.
- Novel vaccine strategies are emerging as a potential non-toxic treatment modality.
Purpose of the Study:
- To explore the efficacy of various immunotherapy vaccine approaches for prostate cancer.
- To evaluate the induction of systemic immune responses against prostate cancer antigens.
Main Methods:
- Utilizing autologous dendritic cell vaccines expressing prostate-specific antigens.
- Investigating granulocyte-macrophage colony-stimulating factor (GM-CSF) modified tumor cell vaccines.
- Exploring poxvirus vaccines and combination therapies (chemotherapy, radiotherapy).
Main Results:
- Autologous dendritic cell vaccines showed promising clinical outcomes in a randomized trial for metastatic castration-resistant prostate cancer.
- Systemic immune responses have been successfully induced against prostate cancer antigens.
Conclusions:
- Vaccine immunotherapy represents a novel, targeted, and potentially non-toxic approach for prostate cancer.
- Further optimization of vaccine strategies and patient selection is necessary, as no single approach is currently superior.
More Related Videos
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

